MAPT and Alzheimer disease: Strengths include the use of a large, harmonized autopsy dataset with detailed neuropathologic and cognitive measures, enabling targeted analysis of neuritic plaque–negative, tau-positive individuals, a biologically distinct and underrepresented group in Alzheimer’s disease research.